Literature DB >> 28195838

The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review.

Massimiliano Buoli1, Silvia Grassi, Valentina Ciappolino, Marta Serati, Alfredo C Altamura.   

Abstract

OBJECTIVE: Traditional pharmacotherapy has undoubtedly improved the outcome of patients with psychiatric disorders, but partial efficacy or poor tolerability persists in a number of these subjects. Among different compounds, zonisamide has been used to address unmet needs of standard pharmacotherapy. The purpose of the present article is to provide a review about the use of zonisamide for the treatment of psychiatric conditions.
METHODS: A research in the main database sources has been conducted to obtain an overview of the use of zonisamide in psychiatric disorders or associated conditions (obesity and smoking cessation).
RESULTS: Most available data indicate the possible effectiveness of zonisamide for the treatment of acute phases of bipolar disorder, binge-eating disorder (BED), alcohol misuse, and obesity. A further assessment of the safety and tolerability of zonisamide is made necessary by the fact that, with the exception of BED, for all other disorders at least some data come from studies with combined pharmacological therapies.
CONCLUSIONS: Zonisamide may have some utility, especially as an adjunctive therapy, for the management of acute phases and weight gain in bipolar disorder and for prevention of alcohol misuse. Preliminary evidence indicates zonisamide as a candidate compound for the treatment of BED and obesity. However, open-label design and small sample sizes of most available studies prevent from drawing sound conclusions about the utility of this compound in psychiatry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28195838     DOI: 10.1097/WNF.0000000000000208

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

1.  Evaluation of the effect of doxasozin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress.

Authors:  Marcelo F Lopez; Sarah E Reasons; Benjamin A Carper; Tracy L Nolen; Rick L Williams; Howard C Becker
Journal:  Alcohol       Date:  2020-07-24       Impact factor: 2.405

2.  Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

Authors:  Karina L Vivar; Kimberly Mancl; Lucia Seminario-Vidal
Journal:  Clin Case Rep       Date:  2017-12-20

3.  Synthesis of some novel coumarin isoxazol sulfonamide hybrid compounds, 3D-QSAR studies, and antibacterial evaluation.

Authors:  Sheida Nasr Esfahani; Mohammad Sadegh Damavandi; Parisa Sadeghi; Zahrasadat Nazifi; Azhar Salari-Jazi; Ahmad Reza Massah
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.